ArticleCell communication and signaling : CCS2026
Loss of protein phosphatase 1 regulator TIMAP protein triggers EMT in A549 cells.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpithelial–mesenchymal transition (EMT) is a cellular reprogramming process that enables epithelial cells to acquire mesenchymal traits, leading to enhanced motility, invasiveness, and resistance to therapy. Transforming growth factor-β-inhibited, membrane-associated protein (TIMAP) is a regulatory subunit of protein phosphatase 1. Altered TIMAP expression has been implicated in tumor progression, suggesting a potential role in EMT.
methodsHuman A549 lung adenocarcinoma cells were subjected to stable lentiviral shRNA-mediated knockdown of TIMAP. Phenotypic, molecular, and functional consequences of TIMAP depletion were assessed using Western blotting, RT-qPCR, high-content imaging, electric cell–substrate impedance sensing, RNA sequencing with pathway enrichment, cytokine array profiling, 3D spheroid assays, trans-endothelial migration assays and metabolic activity measurements. EMT-associated signalling pathways, including TGF-β/SMAD, Wnt/β-catenin, and PI3K/Akt, were examined. Expression and survival correlations were evaluated using publicly available lung adenocarcinoma datasets.
resultsTIMAP knockdown was confirmed at both transcript and protein levels and induced pronounced morphological changes toward a mesenchymal-like phenotype. shTIMAP cells exhibited enhanced attachment, accelerated wound closure, and increased transendothelial migration. Transcriptomic profiling revealed enrichment of EMT-associated pathways. shTIMAP cells displayed reduced epithelial protein markers such as E-cadherin and ZO-1 and increased mesenchymal markers like N-cadherin, Snail, and Slug expression. Activation of EMT-related signalling, including elevated phosphorylation of SMAD2/3, β-catenin, and Akt was also observed. Re-expression of TIMAP or pharmacological inhibition of the TGF-β pathway reversed EMT phenotype. TIMAP depletion altered the secretory profile toward pro-inflammatory, pro-invasive cytokines and disrupted 3D spheroid architecture, promoting spheroid disintegration and invasive outgrowth. TIMAP depletion shifted cellular metabolism from oxidative phosphorylation towards glycolysis and induced cancer stem cell phenotype, with upregulation of CD44, CD133 and downregulation of CD24. Clinically, TIMAP expression is significantly downregulated in lung adenocarcinoma already in early-stage disease, and low tumoral TIMAP levels predict poor survival.
conclusionLoss of TIMAP promotes EMT, enhances motility and invasion, and induces pro-tumorigenic signalling and secretory changes in A549 lung adenocarcinoma cells. These effects likely contribute to the association between low TIMAP expression and adverse patient outcomes, highlighting TIMAP as a potential prognostic biomarker and therapeutic target in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.